Dual incretin agonist: difference between revisions
Diff·revision 21 → 22·13:13, 24 Jun 2025
Difference between revision 21 and revision 22 of Dual incretin agonist. 5 lines changed; the page grew by 614 bytes.
| Revision 21 — 23:11, 3 Jun 2025 DisambigDenzil (talk) rm the comparison to a compound with no published head-to-head data 4,752 bytes ±0 | Revision 22 — 13:13, 24 Jun 2025 Areapercent_Ayo (talk) state which salt form the mass in the infobox refers to 5,366 bytes +614 | ||
|---|---|---|---|
| 32 | None of the three has been isolated experimentally in humans. The trials were designed to establish efficacy, not to partition it.{{r|frias2021}} | 32 | None of the three has been isolated experimentally in humans. The trials were designed to establish efficacy, not to partition it.{{r|frias2021}} |
| 33 | 33 | ||
| + | 34 | == Beyond GIP and GLP-1 == | |
| + | 35 | Other pairings exist. Glucagon/GLP-1 dual agonists — [[Survodutide|survodutide]], efinopegdutide — pair the energy-expenditure and hepatic-fat effects of glucagon-receptor agonism with the appetite and glycaemic effects of GLP-1 agonism, with the GLP-1 component dosed to dominate the glycaemic balance. See [[Glucagon]]. | |
| + | 36 | ||
| + | 37 | Amylin/GLP-1 pairing is achieved differently: [[CagriSema|CagriSema]] is a co-formulation of two separate peptides rather than one molecule, which reintroduces the possibility of differential pharmacokinetics but allows the ratio to be chosen at formulation. | |
| + | 38 | ||
| 34 | == References == | 39 | == References == |
| 35 | {{reflist}} | 40 | {{reflist}} |